The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Androgen Receptor Signaling in Circulating Tumor Cells as a Marker of Hormonally Responsive Prostate Cancer
Open accessAbstract
Androgen deprivation therapy (ADT) is initially effective in treating metastatic prostate cancer, and secondary hormonal therapies are being tested to suppress androgen receptor (AR) reactivation in castration-resistant prostate cancer (CRPC). Despite variable responses to AR pathway inhibitors in CRPC, there are no reliable biomarkers to guide their application. Here, we used microfluidic capture of circulating tumor cells (CTC) to measure AR signaling readouts before and after therapeutic interventions. Single-cell immunofluorescence analysis revealed predominantly “AR-on” CTC signatures in untreated patients, compared with heterogeneous (“AR-on, AR-off, and AR-mixed”) CTC populations in patients with CRPC. Initiation of first-line ADT induced a profound switch from “AR-on” to “AR-off” CTCs, whereas secondary hormonal therapy in CRPC resulted in variable responses. Presence of “AR-mixed” CTCs and increasing “AR-on” cells despite treatment with abiraterone acetate were associated with an adverse treatment outcome. Measuring treatment-induced signaling responses within CTCs may help guide therapy in prostate cancer. Significance: Acquired resistance to first-line hormonal therapy in prostate cancer is heterogeneous in the extent of AR pathway reactivation. Measurement of pre- and posttreatment AR signaling within CTCs may help target such treatments to patients most likely to respond to second-line therapies. Cancer Discov; 2(11); 995–1003. ©2012 AACR. Read the Commentary on this article by Pantel and Alix-Panabières, p. 974. This article is highlighted in the In This Issue feature, p. 961
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
Development of a second-generation antiandrogen for treatment of advanced prostate cancer.
Tran, C., Ouk, S., Clegg, N. J., Chen, Y., Watson, P. A., Arora, V., Wongvipat, J., Smith-Jones, P. M., Yoo, D., Kwon, A., et al. (2009) · Science · doi:10.1126/science.1168175 · Cited by 2,292
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Scher, H. I., Halabi, S., Tannock, I., Morris, M., Sternberg, C. N., Carducci, M. A., Eisenberger, M. A., Higano, C., Bubley, G. J., Dreicer, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.4487 · Cited by 2,241
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip
Stott, S. L., Hsu, C.-H., Tsukrov, D. I., Yu, M., Miyamoto, D. T., Waltman, B. A., Rothenberg, S. M., Shah, A. M., Smas, M. E., Korir, G. K., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1012539107 · Cited by 1,634
Self-citationIn vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C., Koutcher, J., Scher, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,198
Stanbrough, M., Bubley, G. J., Ross, K., Golub, T. R., Rubin, M. A., Penning, T. M., Febbo, P. G., & Balk, S. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4000 · Cited by 1,082
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Androgen Receptor Regulates a Distinct Transcription Program in Androgen-Independent Prostate Cancer
Wang, Q., Li, W., Zhang, Y., Yuan, X., Xu, K., Yu, J., Chen, Z., Beroukhim, R., Wang, H., Lupien, M., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.056 · Cited by 902
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
Danila, D. C., Heller, G., Gignac, G. A., Gonzalez-Espinoza, R., Anand, A., Tanaka, E., Lilja, H., Schwartz, L., Larson, S., Fleisher, M., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1506 · Cited by 665
Stott, S. L., Lee, R. J., Nagrath, S., Yu, M., Miyamoto, D. T., Ulkus, L., Inserra, E. J., Ulman, M., Springer, S., Nakamura, Z., et al. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3000403 · Cited by 539
Self-citationCai, C., He, H. H., Chen, S., Coleman, I., Wang, H., Fang, Z., Chen, S., Nelson, P. S., Liu, X. S., Brown, M., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.001 · Cited by 454
Cai, C., Chen, S., Ng, P., Bubley, G. J., Nelson, P. S., Mostaghel, E. A., Marck, B., Matsumoto, A. M., Simon, N. I., Wang, H., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0532 · Cited by 433
Darshan, M. S., Loftus, M. S., Thadani-Mulero, M., Levy, B. P., Escuin, D., Zhou, X. K., Gjyrezi, A., Chanel-Vos, C., Shen, R., Tagawa, S. T., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1417 · Cited by 432
Self-citationEvans, M. J., Smith-Jones, P. M., Wongvipat, J., Navarro, V., Kim, S., Bander, N. H., Larson, S. M., & Sawyers, C. L. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106383108 · Cited by 316
Self-citationKirby, B. J., Jodari, M., Loftus, M. S., Gakhar, G., Pratt, E. D., Chanel-Vos, C., Gleghorn, J. P., Santana, S. M., Liu, H., Smith, J. P., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0035976 · Cited by 212
Self-citationMechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2009) · Urologic Oncology: Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 204
Effects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
Efstathiou, E., Titus, M., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A., Molina, A., Chieffo, N., Smith, L. A., Karlou, M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7675 · Cited by 189
Helo, P., Cronin, A. M., Danila, D. C., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.117952 · Cited by 138
Genomic Strategy for Targeting Therapy in Castration-Resistant Prostate Cancer
Mendiratta, P., Mostaghel, E. A., Guinney, J., Tewari, A. K., Porrello, A., Barry, W. T., Nelson, P. S., & Febbo, P. G. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.2882 · Cited by 135
Brown, R. S. D., Edwards, J., Doǧan, A., Payne, H. A., Harland, S. J., Bartlett, J. M. S., & Masters, J. R. (2002) · The Journal of Pathology · doi:10.1002/path.1206 · Cited by 90
Imaging Androgen Receptor Signaling with a Radiotracer Targeting Free Prostate-Specific Antigen
Ulmert, D., Evans, M. J., Holland, J. P., Rice, S. L., Wongvipat, J., Pettersson, K. S. I., Abrahamsson, P.-A., Scardino, P. T., Larson, S. M., Lilja, H. G., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0316 · Cited by 76
Nagrath, S., Stott, S. L., Lee, R. J., Yu, M., Ulkus, L., Iafrate, J., Smith, M. R., Tompkins, R. G., Sequist, L. V. D., Haber, D. A., et al. (2010) · Cancer Research · doi:10.1158/1538-7445.am10-1136 · Cited by 34
Self-citation
Cited by
Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis
Aceto, N., Bardia, A., Miyamoto, D. T., Donaldson, M. C., Wittner, B. S., Spencer, J. A., Yu, M., Pely, A., Engstrom, A., Zhu, H., et al. (2014) · Cell · doi:10.1016/j.cell.2014.07.013 · Cited by 2,441
Self-citationClinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
Alix-Panabières, C., & Pantel, K. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-1483 · Cited by 1,394
Challenges in circulating tumour cell research
Alix-Panabières, C., & Pantel, K. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3820 · Cited by 1,300
Ozkumur, E., Shah, A. M., Ciciliano, J. C., Emmink, B. L., Miyamoto, D. T., Brachtel, E., Yu, M., Chen, P.-I., Morgan, B., Trautwein, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005616 · Cited by 1,086
Self-citationAttard, G., Parker, C., Eeles, R. A., Schröder, F., Tomlins, S. A., Tannock, I., Drake, C. G., & de Bono, J. S. (2016) · The Lancet · doi:10.1016/s0140-6736(14)61947-4 · Cited by 905
Metadata
- Authors
- Miyamoto, D. T., Lee, R. J., Stott, S. L., Ting, D. T., Wittner, B. S., Ulman, M., Smas, M. E., Lord, J. B., Brannigan, B. W., Trautwein, J., Bander, N. H., Wu, C.-L., Sequist, L. V., Smith, M. R., Ramaswamy, S., Toner, M., Maheswaran, S., & Haber, D. A.
- Venue
- Cancer Discovery
- Published
- 2012-11-01
- Volume
- 2
- Issue
- 11
- Pages
- 995-1003
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- OpenAlex
- W2110735634
- Cited by
- 272
- References
- 24
- FWCI
- 22.06
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.